The purpose of this study will be to evaluate the safety, tolerability, and pharmacological activity of pemigatinib in patients with advanced malignancies.
This trial is currently open and accepting patients.
The following criteria is a partial list of reasons why patients may be eligible to participate in this clinical trial. Further evaluation with a medical professional is required.
Enrollment: 256 patients (estimated)View More
January 01, 2018
In part 1, no pts had a complete response (CR) or partial response (PR); 9 and 8 pts had stable disease (SD) and progressive disease (PD), respectively. In part 2, most common tumors were cholangiocarcinoma (CCA; n=9), breast (n=8), and esophageal, ovarian, and head and neck (each n=3); 3 pts (with CCA) had a PR (9 mg QD, n=1; 13.5 mg QD, n=2); 9 and 14 pts had SD and PD, respectively.
View all clinical trial locations sorted by state.
Port St. Lucie, FL
San Antonio, TX
If you are interested in keeping an eye on this trial, you can add it to your list of favorite trials. We'll send you alerts when this trial is updated.
You can explore trial locations from around the US and connect directly with a trial coordinator.Find Nearby Locations
You can print an overview of this trial to take in to your next appointment. Your doctor can help you understand if this trial may be right for you.
Still need help? Send us a message